Clinical Trials Browser

binimetinib × Breast × Clear all

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05111561 2026-05-13

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase 1 Suspended

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03971409 2026-04-17

InCITe

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05554354 2026-03-03

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Phase 2 Terminated

Anatomic Stage IV Breast Cancer AJCC v8

NCT03106415 2025-06-27

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

23 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04494958 2025-03-24

PALBOBIN

Phase 1/2 Completed

24 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT01337765 2020-10-09

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Phase 1 Completed

BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Phase 1 Completed

BreastGastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms